keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/28620064/sleep-disturbance-in-psoriatic-disease-prevalence-and-associated-factors
#1
Ian T Y Wong, Vinod Chandran, Suzanne Li, Dafna D Gladman
OBJECTIVE: We aimed to determine the prevalence and quality of sleep in patients with psoriatic arthritis (PsA) and those with psoriasis without PsA (PsC) followed in the same center, to identify factors associated with sleep disturbance, and to compare findings to those of healthy controls (HC). METHODS: The study included 113 PsA [ClASsification for Psoriatic ARthritis (CASPAR) criteria] and 62 PsC (PsA excluded by a rheumatologist) patients and 52 HC. Clinical variables were collected using a standard protocol...
June 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28609161/the-efficacy-of-short-term-clobetasol-lotion-in-the-treatment-of-scalp-psoriasis
#2
Ali Rajabi-Estarabadi, Hournaz Hasanzadeh, Arash Taheri, Steven R Feldman, Alireza Firooz
BACKGROUND: Scalp psoriasis can have a considerable impact on patients' quality of life and is considered difficult to treat. Treatment failure may, however, be due to poor adherence, as application of topical treatments to hair bearing areas is difficult and time consuming and also poor commination between physician and patient. OBJECTIVE: To assess the efficacy of short term treatment of scalp psoriasis with topical clobetasol lotion. MATERIALS AND METHODS: 12 patients with mild to severe scalp psoriasis were recruited for this study...
June 13, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28608530/psoriasis-in-latin-america-and-the-caribbean-a-systematic-review
#3
REVIEW
A Hernández-Vásquez, L Molinari, N Larrea, A Ciapponi
BACKGROUND: Psoriasis is a chronic inflammatory disease that generally affects the skin, nails and joints. The burden of psoriatic disease in Latin America and the Caribbean (LAC) remains largely unknown. OBJECTIVE: To estimate the burden of psoriasis in LAC. METHODS: We conducted a systematic review following the MOOSE and PRISMA statements. We searched published studies in MEDLINE, EMBASE, LILACS, and CENTRAL from January 1, 2000 to August 5, 2015...
June 13, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28606711/impact-of-atopic-dermatitis-on-health-related-quality-of-life-and-productivity-in-adults-in-the-united-states-an-analysis-using-the-national-health-and-wellness-survey
#4
Laurent Eckert, Shaloo Gupta, Caroline Amand, Abhijit Gadkari, Puneet Mahajan, Joel M Gelfand
BACKGROUND: Given its public health impact, there is need for broad and representative data on the humanistic burden of atopic dermatitis (AD). OBJECTIVE: To establish the humanistic burden of AD in US adults. METHODS: Data were from the 2013 US National Health and Wellness Survey; AD self-reports were propensity-matched with non-AD controls and with psoriasis controls. Bivariate analyses were conducted on burden outcomes between the AD and control groups...
June 9, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28602039/secukinumab-demonstrates-greater-sustained-improvements-in-daily-activities-and-personal-relationships-than-ustekinumab-in-patients-with-moderate-to-severe-plaque-psoriasis-52-week-results-from-the-clear-study
#5
A Blauvelt, K Reich, S Mehlis, F Vanaclocha, H Sofen, W Abramovits, Y Zhao, I Gilloteau, E Davenport, N Williams, A Guana, S Tyring
BACKGROUND: Psoriasis can greatly impact patients' lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin-17A, has demonstrated good efficacy and safety in the treatment of moderate-to-severe psoriasis and psoriatic arthritis with a rapid onset of action and sustained response. OBJECTIVE: This analysis using the CLEAR study, a phase 3b double-blind study comparing the efficacy and safety of secukinumab versus ustekinumab in adults with moderate-to-severe plaque psoriasis, evaluated the treatment effects on patient's daily activities and personal relationships...
June 11, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28597182/apremilast-a-novel-oral-treatment-for-psoriasis-and-psoriatic-arthritis
#6
REVIEW
Tiago Torres, Luis Puig
Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and negative impacts on a patient's quality of life. Despite the advances in biologic therapy, there are still unmet needs in the treatment of psoriasis, as current treatments are limited in terms of long-term efficacy, tolerability, safety, route of administration, and cost. Apremilast is an oral, small-molecule phosphodiesterase 4 inhibitor that works intracellularly by blocking the degradation of cyclic adenosine 3',5'-monophosphate, resulting in increased intracellular cyclic adenosine 3',5'-monophosphate levels in phosphodiesterase 4-expressing cells...
June 8, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28580646/secukinumab-is-superior-to-fumaric-acid-esters-in-treating-subjects-with-moderate-to-severe-plaque-psoriasis-who-are-na%C3%A3-ve-to-systemic-treatments-results-from-the-randomized-controlled-prime-trial
#7
M Sticherling, U Mrowietz, M Augustin, D Thaçi, N Melzer, C Hentschke, J Kneidl, C Sieder, K Reich
BACKGROUND: Secukinumab is a fully human antibody that neutralizes IL-17A and has significant efficacy and a favorable safety profile in moderate to severe plaque psoriasis and psoriatic arthritis. METHODS: In this 24-week, randomized, open-label, multicenter study with blinded assessment, subjects with moderate to severe plaque psoriasis, naïve to systemic treatments, were randomized to receive secukinumab 300 mg subcutaneously or oral fumaric acid esters (FAE)...
June 5, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28580579/secukinumab-sustains-good-efficacy-and-favourable-safety-in-moderate-to-severe-psoriasis-up-to-3-years-of-treatment-results-from-a-double-blind-extension-study
#8
R Bissonnette, T Luger, D Thaçi, D Toth, I Messina, R You, A Guana, T Fox, C Papavassilis, I Gilloteau, U Mrowietz
BACKGROUND: Secukinumab has demonstrated significant efficacy with a good safety profile through 1 year in plaque psoriasis. Given the chronic nature of this disease, long-term follow-up is needed to fully evaluate psoriasis therapies. OBJECTIVES: Determine long-term (3-year) efficacy/safety of secukinumab in moderate-to-severe psoriasis. METHODS: Subjects completing 52 weeks of secukinumab treatment in the SCULPTURE core study entered an extension in which they continued the same double-blind regimens...
June 5, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28573743/impact-of-ixekizumab-treatment-on-skin-related-personal-relationship-difficulties-in-moderate-to-severe-psoriasis-patients-12-week-results-from-two-phase-3-trials
#9
L Guenther, R B Warren, J C Cather, H Sofen, Y Poulin, M Lebwohl, T Terui, A Potts Bleakman, B Zhu, R Burge, K Reich, P van de Kerkhof
BACKGROUND: Psoriasis symptoms may decrease quality of life for patients. Skin-related personal relationship difficulties in psoriasis patients are common, under-reported, and poorly understood. OBJECTIVE: To assess the effect of ixekizumab (IXE) treatment on skin-related personal relationship difficulties in patients with moderate-to-severe psoriasis. METHODS: Pooled data (N=2570) on skin-related relationship problems were obtained from two large phase 3 trials (UNCOVER-2 and UNCOVER-3) in patients with moderate-to-severe plaque psoriasis randomized to subcutaneous placebo (PBO, N=361), etanercept (ETN; 50 mg twice weekly, N=740), or 80 mg IXE as one injection every 4 (IXEQ4W, N=733) or 2 weeks (IXEQ2W, N=736) for 12 weeks, following a 160-mg initial dose...
June 2, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28567556/minimal-disease-activity-in-patients-with-psoriatic-arthritis-treated-with-ustekinumab-results-from-a-24-week-real-world-study
#10
Maddalena Napolitano, Luisa Costa, Francesco Caso, Matteo Megna, Raffaele Scarpa, Nicola Balato, Fabio Ayala, Anna Balato
Psoriatic arthritis (PsA) is a chronic inflammatory joint disease affecting around 40% of psoriasis patients. Minimal disease activity (MDA) criteria have been proposed to identify a state of low disease activity, one of the principal goals of treatment for psoriatic disease. This study investigated treatment with ustekinumab (UST) in the context of a real-world setting. Thirty-four PsA patients who had failure or inadequate response to conventional synthetic disease-modifying antirheumatic drugs or to anti-tumour necrosis factor alpha were enrolled...
May 31, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28567508/-psoriasis-capitis-and-seborrhoic-eczema-of-scalp-diseases
#11
REVIEW
M Sticherling
The scalp may be affected by various diseases with equally varying manifestations. Erythema and scaling is often accompanied by agonizing itch. Scalp psoriasis and seborrheic eczema represent the most frequent diseases, which can be differentiated into classical cases; however, overlap and similarities are seen. Sharply demarcated erythematosquamous plaques across the natural hairline in psoriasis are opposed to blurred dark-red erythema and yellowish, greasy scales in seborrheic eczema. Whereas with the latter diffuse alopecia may frequently be found, hair loss is rarely seen in psoriasis and may also be related to therapeutic agents...
June 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28557781/management-of-psoriasis-with-a-xematop-topical-compounded-formula-a-case-report
#12
Nat Jones, Maria Carvalho, Andrea Branvold-Herr
Skin conditions such as psoriasis and eczema negatively impact the patient's quality of life; the primary goal of topical treatments is to minimize the disease-specific symptoms. This case report discusses the management of two refractory psoriasis skin lesions in an adult male using a topical compounded formula. The psoriasis symptoms were assessed quantitatively using two validated research instruments, the Psoriasis Symptom Inventory, and an adapted Numeric Rating Scale. A qualitative assessment was also performed by evaluating the digital photographs taken by the patient during the course of treatment...
May 2017: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/28550824/-analysis-of-the-cochrane-review-topical-treatments-for-scalp-psoriasis-cochrane-database-syst-rev-2016-2-cd009687
#13
Catarina Soares Queirós, Gonçalo Silva Duarte, João Costa, António Vaz-Carneiro
Regardless the psoriasis subtype, up to 79% of people with this skin condition present scalp involvement, which is often the first site to show symptoms of the disease. In addition to being itchy, the red and scaly lesions are usually easy to see, and may be embarrassing. Topical therapy is usually the first line of treatment; however the wide array of available interventions can make the choice difficult, and may even lead to an inadequate treatment. The objective of this review was to evaluate the efficacy and safety of topical treatments for scalp psoriasis...
March 31, 2017: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/28542874/comparison-of-ixekizumab-with-ustekinumab-in-moderate-to-severe-psoriasis-24-week-results-from-ixora-s-a-phase-3-study
#14
K Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm, S Hartz, C Paul
BACKGROUND: The interleukin (IL)-23/IL-17 axis has been shown critical in the pathogenesis of psoriasis. OBJECTIVES: To present the primary endpoint (Week 12) and safety/efficacy data up to Week 24 from a head-to-head trial (IXORA-S) of the IL-17A inhibitor, ixekizumab (IXE), vs. the IL-12/23 inhibitor ustekinumab (UST). METHODS: Randomised patients received IXE (160-mg starting dose, then 80 mg every two weeks for 12 weeks, then 80 mg every four weeks, N=136) or UST (45 mg/90 mg weight-based dosing per label, N=166)...
May 19, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28541870/palmoplantar-pustulosis-a-cross-sectional-analysis-in-germany
#15
Dagmar Wilsmann-Theis, Arnd Jacobi, Yvonne Frambach, Sandra Philipp, Ansgar Weyergraf, Tillmann Schill, Kirsten Steinz, Sascha Gerdes, Rotraut Mössner
BACKGROUND: Palmoplantar pustulosis (PPP) is a recalcitrant chronic inflammatory skin disease. Data relevant for the medical care of patients with PPP are scarce. Thus, the aim of this work was to investigate the disease burden, clinical characteristics, and comorbidity of PPP patients in Germany. PATIENTS AND METHODS: PPP patients were examined in a crosssectional study at seven specialized psoriasis centers in Germany. RESULTS: Of the 172 included patients with PPP, 79...
April 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28541484/residual-disease-activity-in-psoriatic-arthritis-discordance-between-the-rheumatologist-s-opinion-and-minimal-disease-activity-measurement
#16
Leonieke J J van Mens, Maureen C Turina, Marleen G H van de Sande, Mike T Nurmohamed, Arno W R van Kuijk, Dominique L P Baeten
Objective.: To assess how many PsA patients with an acceptable disease state according to the treating rheumatologist have quiescent disease defined as minimal disease activity (MDA). Methods.: This cross-sectional study included 250 PsA patients. To assess current clinical practice as closely as possible, acceptable disease state was not determined by predefined activity measures, but instead was defined by asking rheumatologists to refer those patients whom they considered sufficiently treated...
May 24, 2017: Rheumatology
https://www.readbyqxmd.com/read/28541239/psychological-parameters-of-psoriasis
#17
A Kouris, E Platsidaki, C Kouskoukis, C Christodoulou
Psoriasis is a chronic, inflammatory scaling dermatosis. The marked visible appearance of the lesions have a negative impact on body image that leads to decreased self-esteem, hence seriously compromising the patient's quality of life. The clinical picture critically affects the social well-being of the patient since the disease is commonly misunderstood and feared by the social environment as being contagious. The patient feels stigmatized and this further intensifies their lack of self-confidence and self-esteem...
January 2017: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/28540870/atorvastatin-as-adjunctive-therapy-for-chronic-plaque-type-psoriasis-versus-betamethasone-valerate-alone-a-randomized-double-blind-placebo-controlled-trial
#18
Sharlene Helene H Chua, Giselle Marie S Tioleco, Carmela Augusta F Dayrit, Winlove P Mojica, Belen L Dofitas, Lorna F Frez
BACKGROUND: Psoriasis is a T helper 1 cell-mediated chronic inflammation. Statins have been found to have anti-inflammatory and immunomodulatory effects targeting T helper 1 cells and thus, are being investigated as treatments for psoriasis. AIMS: To investigate the efficacy and safety of atorvastatin as adjunctive treatment for mild to moderate chronic plaque psoriasis; and the impact of atorvastatin on quality of life. The study also aimed to correlate the beneficial effects of atorvastatin with its lipid-lowering effects...
July 2017: Indian Journal of Dermatology, Venereology and Leprology
https://www.readbyqxmd.com/read/28534601/management-of-psoriatic-arthritis-psa-among-cutaneous-psoriasis-from-pathogenesis-to-therapy
#19
Pauline Hoelt, Cyrille Confavreux, Denis Jullien, Axel P Villani
Psoriatic arthritis (PsA) is an inflammatory rheumatism belonging to spondylarthritis family and which occurs in about 30% of patients with psoriasis. The pathogenesis entails a genetic predisposition, environmental and immunologic factors. Most of the time, cutaneous lesions precede apparition of articular manifestations and dermatologists who treat psoriatic patients have to regularly screen for early PsA, especially in patients with risk factors (notably nail psoriasis). Early detection greatly increases the chances for successful treatment and can prevent slow joint destruction...
May 23, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28528371/assessment-of-the-psychometric-properties-of-the-eq-5d-3l-and-eq-5d-5l-instruments-in-psoriasis
#20
John Yfantopoulos, Athanasios Chantzaras, Stathis Kontodimas
The aim of this study was to assess the psychometric properties of the five-level (EQ-5D-5L) in comparison with the standard three-level (EQ-5D-3L) classification systems of the EQ-5D in a sample of psoriatic patients. Psoriatic subjects (n = 396) recruited from 16 private practicing centers from various areas of Greece self-completed the two EQ-5D versions and the Dermatology Life Quality Index, while information was also collected on socio-demographics, clinical characteristics and comorbidities. The EQ-5D-5L and EQ-5D-3L were evaluated in terms of agreement, feasibility, ceiling effects, redistribution properties, inconsistency, informativity, and convergent and known-groups validity...
May 20, 2017: Archives of Dermatological Research
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"